PPT-Subjects with Renal Impairment Switching from Tenofovir Disoproxil Fumarate to Tenofovir

Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Have Improved Renal and Bone Safety through 48 Weeks Study GSUS2920112 Samir K Gupta 1 Anton Pozniak 2 Jose Arribas. An HIV pre-exposure prophylaxis trial in Thailand: . participant adherence and study results . National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Division of HIV/AIDS Prevention. A collaborative project involving: The Bangkok Metropolitan Administration, the. M Harris, . S Guillemi. , K Chan, B Yip. ,. . M Hull, V Dias Lima, R Hogg, J . Montaner. Abstract #: WEAB0202. Organ Dysfunction in HIV: It's . Complicated. Wednesday, 3 July 2013 14:30-16:. 00. Session . New Treatments for HIV. C. Ryan Tomlin, . Pharm.D. ., BCPS, AAHIVP. Mercy Health Saint Mary’s. Grand Rapids, Michigan. Outline. Newly Released Antiretroviral Medications. Isentress. HD. ® (. raltegravir. Treatment-naïve Patients . Clinical Instructor, Harvard Medical School. Director of Research, CRI New England. Vice Chair, INSIGHT Scientific Steering Committee. Boston, USA . Calvin Cohen, MD, MSc. A.Dravid. 1. ,A.Sadre. 2. ,S.Dhande. 1. , A.Borkar. 1. ,M.Kulkarni. 1. ,M.Dravid. 3. 1. . Ruby hall clinic, Department of HIV Medicine, . Pune. , India. 2. Ruby hall clinic, Department of Nephrology, . of HIV. . Convenience, tolerability, simplicity. New & Investigational Agents. “Quad” Pill- . Stribild. Released by FDA 08-27-12. Tenofovir Emtricitabine Cobicistat Elvitegravir. “Booster”. Program. Improving Health. . . Promoting Wellness. QUARTERLY . SUMMARY. 1. st. Quarter. APRIL-JUNE 2017. 2017/2018 Ryan White Grant Year. COUNTY HEALTH DEPARTMENTS . BY PHARMACY CATEGORY. PUTNAM. MARION. in a Single-Tablet Regimen . in Initial HIV-1 Therapy. Combined Primary Results of . Studies GS-US-292-0104 and GS-US-292-0111. David Wohl. 1. , Anton Pozniak. 2. , Melanie Thompson. 3. , Edwin DeJesus. Tenofovir. . Alafenamide. . vs. . Tenofovir. . Disoproxil. . Fumarate. Combined Safety Results of . Studies GS-US-292-0104 and GS-US-292-0111. Paul Sax. 1. , Michael Saag. 2. , Michael Yin. 3. , Frank Post. fumarate and . emtricitabine. tablets obtained from the internet – are they what they say they are?. Xinzhu Wang. 1. , Will Nutland. 2. , Michael Brady. 3. , Ian Green. 3. , Myra McClure. 1. , Marta Boffito. TOTEM. Switching the NRTI Backbone to Tenofovir DF-Emtricitabine. TOTEM: Study Design. Source. : . Valantin. MA, et al. . J . Antimicrob. . Chemother. . 2010;65:556-61.. TDF-FTC + Continue . 3. rd. ADONE Trial. Simplification to Efavirenz-Tenofovir DF-Emtricitabine . ADONE: Study Design. Source: . Airoldi. M, et al. Patient Prefer Adherence. 2010;4:115-25.. Study Design: ADONE Study . Background. FTC. Study 311-1089. Switching from TDF/FTC to TAF/. FTC. Study 311: Design. Source. : Gallant JE, et al. Lancet HIV. 2016;3:e158-65.. Switch to TAF/FTC*. . (n = 333). Continue TDF/FTC. (n = 330). *Patients on a pharmacokinetic booster (ritonavir) received tenofovir alafenamide-emtricitabine 10/200 mg. Alafenamide. in Renal Impairment. A Pozniak. 1. , J Arribas. 2. , . SK Gupta. 3. , . FA Post. 4. , A Avihingsanon. 5. , . G Crofoot. 6. , . K Lichtenstein. 7. , M Ramgopal. 8. , P Chetchotisakd. 9. , MW Fordyce.